Cytek Biosciences Inc (CTKB)
Cash ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | US$ in thousands | 98,716 | 162,272 | 177,918 | 169,141 | 167,630 | 163,629 | 131,544 | 129,476 | 296,601 | 341,523 | 349,894 | 362,506 | 364,618 | 376,771 | 159,846 | 168,584 | 165,231 |
| Short-term investments | US$ in thousands | 179,145 | 115,505 | 99,323 | 101,298 | 95,111 | 124,392 | 167,294 | 169,519 | 44,548 | — | — | — | — | — | — | — | — |
| Total current liabilities | US$ in thousands | 67,663 | 62,797 | 52,379 | 55,566 | 56,226 | 58,693 | 53,591 | 56,517 | 49,040 | 41,494 | 42,350 | 42,803 | 32,160 | 29,839 | 28,165 | 27,764 | 26,536 |
| Cash ratio | 4.11 | 4.42 | 5.29 | 4.87 | 4.67 | 4.91 | 5.58 | 5.29 | 6.96 | 8.23 | 8.26 | 8.47 | 11.34 | 12.63 | 5.68 | 6.07 | 6.23 |
December 31, 2024 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($98,716K
+ $179,145K)
÷ $67,663K
= 4.11
The cash ratio of Cytek Biosciences Inc has fluctuated over the reporting periods provided. The ratio measures the company's ability to cover its current liabilities with its cash and cash equivalents.
From December 31, 2020, to December 31, 2022, the cash ratio generally remained above 6, indicating a strong ability to cover its short-term obligations with cash on hand. The peak in this period was on September 30, 2021, and December 31, 2021, reaching 12.63 and 11.34, respectively.
However, from March 31, 2023, the cash ratio started to decline, with values falling below 6. This downward trend continued until December 31, 2024, indicating a potential decrease in the company's ability to cover its short-term liabilities with cash and cash equivalents. The lowest point during this period was on December 31, 2024, with a cash ratio of 4.11.
Overall, while Cytek Biosciences Inc had a strong cash ratio in the earlier years, the declining trend in the latter years may suggest a need for the company to assess its liquidity position and possibly take measures to improve its cash reserves relative to its current liabilities.
Peer comparison
Dec 31, 2024